Latest news, Wikipedia summary, and trend analysis.
This topic has appeared in the trending rankings 1 time(s) in the past year. While it does not trend frequently, its appearance suggests a renewed or concentrated surge of public interest.
Based on Wikipedia pageviews and search interest, this topic gained significant attention on the selected date.
E2511 entered the ranking for the first time today at position #. This is its highest position ever recorded.
This topic has appeared in the English Wikipedia rankings 1 time. It first appeared on 2026-07-16 and was most recently seen on 2026-07-16.
E2511, or E-2511, is a selective biased tropomyosin receptor kinase A (TrkA) positive allosteric modulator which is under development for the treatment of Alzheimer's disease. It is taken orally. The drug has been found to increase cholinergic signaling in preclinical research. The elimination half-life of E2511 is 3.2 hours in humans. E2511 is under development by Eisai. As of September 2024, it is in phase 1 clinical trials for Alzheimer's disease. A phase 1 clinical trial has been completed. The chemical structure of E2511 does not yet appear to have been disclosed.
Read more on Wikipedia →No recent news articles found.
This topic has recently gained attention due to increased public interest. Search activity and Wikipedia pageviews suggest growing global engagement.
Search interest data over the past 12 months indicates that this topic periodically attracts global attention. Sudden spikes often correlate with major news events, public statements, or geopolitical developments.